NEOGENOMICS INC Files DEF 14A with Executive Compensation Details
Ticker: NEO · Form: DEF 14A · Filed: Apr 8, 2024 · CIK: 1077183
Sentiment: neutral
Topics: DEF 14A, Executive Compensation, Equity Awards, NEOGENOMICS INC, Shareholder Vote
TL;DR
<b>NEOGENOMICS INC files its DEF 14A, detailing executive compensation and equity awards for the 2023 fiscal year.</b>
AI Summary
NEOGENOMICS INC (NEO) filed a Proxy Statement (DEF 14A) with the SEC on April 8, 2024. Filing is a Definitive Proxy Statement (DEF 14A) for the fiscal year ending December 31, 2023. Details executive compensation for key personnel including Christopher Smith, Lynn Tetrault, Mark Mallon, and Douglas VanOort. Includes information on equity awards granted and outstanding during the fiscal year 2023. Covers compensation components such as deductions and equity award additions for PEO and Non-PEO members. The company is NEOGENOMICS INC, ticker NEO, incorporated in Nevada.
Why It Matters
For investors and stakeholders tracking NEOGENOMICS INC, this filing contains several important signals. This filing provides shareholders with crucial information regarding how executive compensation is structured and awarded, impacting potential shareholder votes on executive pay. Understanding the equity awards and compensation breakdown is key to assessing management's alignment with shareholder interests and the company's overall financial health.
Risk Assessment
Risk Level: — NEOGENOMICS INC shows moderate risk based on this filing. The filing is a routine DEF 14A, but the complexity of executive compensation and equity awards could present risks if not clearly understood by shareholders.
Analyst Insight
Shareholders should carefully review the executive compensation details and equity award grants to make informed voting decisions.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Christopher Smith | Member | |
| Lynn Tetrault | Member | |
| Mark Mallon | Member |
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting Period)
- 2024-04-08 — Filing Date (Date of Report)
- 29 — Public Document Count (Number of documents filed)
Key Players & Entities
- NEOGENOMICS INC (company) — Filer
- Christopher Smith (person) — Executive
- Lynn Tetrault (person) — Executive
- Mark Mallon (person) — Executive
- Douglas VanOort (person) — Executive
- 2023-12-31 (date) — Fiscal Year End
- 2024-04-08 (date) — Filing Date
- DEF 14A (document_type) — Filing Type
FAQ
When did NEOGENOMICS INC file this DEF 14A?
NEOGENOMICS INC filed this Proxy Statement (DEF 14A) with the SEC on April 8, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by NEOGENOMICS INC (NEO).
Where can I read the original DEF 14A filing from NEOGENOMICS INC?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by NEOGENOMICS INC.
What are the key takeaways from NEOGENOMICS INC's DEF 14A?
NEOGENOMICS INC filed this DEF 14A on April 8, 2024. Key takeaways: Filing is a Definitive Proxy Statement (DEF 14A) for the fiscal year ending December 31, 2023.. Details executive compensation for key personnel including Christopher Smith, Lynn Tetrault, Mark Mallon, and Douglas VanOort.. Includes information on equity awards granted and outstanding during the fiscal year 2023..
Is NEOGENOMICS INC a risky investment based on this filing?
Based on this DEF 14A, NEOGENOMICS INC presents a moderate-risk profile. The filing is a routine DEF 14A, but the complexity of executive compensation and equity awards could present risks if not clearly understood by shareholders.
What should investors do after reading NEOGENOMICS INC's DEF 14A?
Shareholders should carefully review the executive compensation details and equity award grants to make informed voting decisions. The overall sentiment from this filing is neutral.
Risk Factors
- Proxy Statement Filing Requirements [medium — regulatory]: The company must comply with SEC regulations for filing DEF 14A, ensuring all required information on executive compensation and corporate governance is accurately disclosed.
- Executive Compensation Structure [medium — financial]: The structure and amount of executive compensation, including equity awards, can impact the company's financial performance and shareholder value.
- Disclosure Accuracy [medium — operational]: Ensuring the accuracy and completeness of all disclosed information in the proxy statement is critical to avoid potential legal or reputational issues.
Key Dates
- 2024-04-08: Filing Date — Definitive Proxy Statement (DEF 14A) filed for the fiscal year ending 2023-12-31.
Filing Stats: 4,373 words · 17 min read · ~15 pages · Grade level 16 · Accepted 2024-04-08 16:06:54
Filing Documents
- neo-20240408.htm (DEF 14A) — 1395KB
- neo-20240408_g1.jpg (GRAPHIC) — 364KB
- neo-20240408_g10.jpg (GRAPHIC) — 85KB
- neo-20240408_g11.jpg (GRAPHIC) — 113KB
- neo-20240408_g12.jpg (GRAPHIC) — 105KB
- neo-20240408_g13.jpg (GRAPHIC) — 109KB
- neo-20240408_g14.jpg (GRAPHIC) — 105KB
- neo-20240408_g15.jpg (GRAPHIC) — 110KB
- neo-20240408_g2.jpg (GRAPHIC) — 11KB
- neo-20240408_g3.jpg (GRAPHIC) — 46KB
- neo-20240408_g4.jpg (GRAPHIC) — 52KB
- neo-20240408_g5.jpg (GRAPHIC) — 77KB
- neo-20240408_g6.jpg (GRAPHIC) — 10KB
- neo-20240408_g7.jpg (GRAPHIC) — 44KB
- neo-20240408_g8.jpg (GRAPHIC) — 50KB
- neo-20240408_g9.jpg (GRAPHIC) — 76KB
- 0001077183-24-000042.txt ( ) — 5766KB
- neo-20240408.xsd (EX-101.SCH) — 5KB
- neo-20240408_def.xml (EX-101.DEF) — 8KB
- neo-20240408_lab.xml (EX-101.LAB) — 11KB
- neo-20240408_pre.xml (EX-101.PRE) — 7KB
- neo-20240408_htm.xml (XML) — 293KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 27 Compensation Discussion and Analysis 27 Culture and Compensation Committee Report 42
Executive Compensation Tables
Executive Compensation Tables 43 Summary Compensation Table 43 Grants of Plan-Based Awards 44 Narrative Disclosure to the Summary Compensation Table and the Grants of Plan Awards Table 45 Options Exercised and Stock Vested 46 Outstanding Equity Awards on December 31, 2023 47 Employment Agreements and Potential Payments Upon Termination or Change in Control 48 Chief Executive Officer Pay Ratio 50 Pay Versus Performance 51 Equity Compensation Plan Information 56
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 57 FUTURE STOCKHOLDER PROPOSALS 59 TRANSACTIONS WITH RELATED PERSONS 60 OTHER MATTERS 61 IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 202 4 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 23, 2024 62 QUESTIONS AND ANSWERS ABOUT THE 2024 ANNUAL MEETING 63 ANNEX A: FOURTH AMENDMENT OF THE NEOGENOMICS, INC. EMPLOYEE STOCK PURCHASE PLAN (AMENDED AND RESTATED EFFECTIVE JUNE 1, 2018) A-1 Index of Frequently Requested Information Auditor Fees 21 Board Leadership Structure 4 CEO Pay Ratio 50 Clawback Policy 18 Compensation Design 29 Culture and Compensation Governance 31 Director Attendance 13 Director Independence 5 Director Qualifications 8 Managing Compensation Related Risks 32 Nominee Biographies 8 Pay Versus Performance 51 Risk Oversight 6 Stockholder Engagement 34 Stockholder Engagement on the 202 3 Say-on-Pay Vote 34 Summary Compensation Table 43 Use of an Independent Advisor 32 NEOGENOMICS, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics," or the "Company"), having its principal executive offices at 9490 NeoGenomics Way, Fort Myers, Florida 33912, is providing these proxy materials in connection with the 2024 Annual Meeting of Stockholders of NeoGenomics (the "2024 Annual Meeting"). This Proxy Statement contains important information for you to consider when deciding how to vote on the matters brought before the 2024 Annual Meeting. This Proxy Statement, including the notice of the 2024 Annual Meeting (the "Meeting Notice") and the proxy card, were first distributed to our stockholders on or about April 8, 2024. The following is a summary of key disclosures in our Proxy Statement. This is only a summary and may not contain all the information that is important to you. For more complete information, please review the full Proxy Stateme